Roche Early-Stage Hep C Candidates Show Promise At AASLD
This article was originally published in Pharmaceutical Approvals Monthly
As Roche aims to maintain a strong position in the hepatitis C market amid the emergence of new treatment mechanisms, the company is seeking to move forward clinical-stage polymerase and protease inhibitors in development.
You may also be interested in...
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.